Wiadomosci lekarskie (Warsaw, Poland : 1960) · 2024
Effectiveness of the quercetin use in patients with COVID-19 with concomitant type 2 diabetes mellitus.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tylishchak Zoriana, Pryshliak Oleksandra, Boichuk Oleksandr, Fedorov Sergiy, Protsyk Andrii, Kobryn Taras, Miziuk Ruslan
Аннотация
OBJECTIVE: Aim: To conduct a comparative analysis of the effectiveness of basic therapy and basic therapy with the inclusion of quercetin in patients with COVID-19 with concomitant type 2 diabetes.
PATIENTS AND METHODS: Materials and Methods: There were examined 60 patients with COVID-19 with concomitant T2DM. Upon admission into the hospital and again after 10 days, serum levels of interleukin-6, C-reactive protein, procalcitonin, ferritin, endothelin-1 were determined, and capillaroscopy of the nail plate was performed. Patients of the group I (30) against the background of protocol therapy received 0.5 g of quercetin intravenously once a day for 10 days. Patients of the group II (30) received to basic therapy.
RESULTS: Results: After the treatment in patients of the group I general weakness decreased, body temperature normalized, improved saturation indicators, the level of acute-phase parameters (interleukin-6, CRP and ferritin) significantly decreased, a positive effect of quercetin on the level of D-dimer in blood serum was noted, indices of pericapillary edema and hemosiderin deposition significantly decreased, indices diameter of the arterial part of the capillary and capillary network density significantly increased.
CONCLUSION: Conclusions: The use of quercetin against the background of basic therapy in patients with COVID-19 and concomitant T2DM reliably reduces the level of acute-phase indices, has an important clinical significance for reducing endothelial dysfunction and for preventing thrombotic complications.
PATIENTS AND METHODS: Materials and Methods: There were examined 60 patients with COVID-19 with concomitant T2DM. Upon admission into the hospital and again after 10 days, serum levels of interleukin-6, C-reactive protein, procalcitonin, ferritin, endothelin-1 were determined, and capillaroscopy of the nail plate was performed. Patients of the group I (30) against the background of protocol therapy received 0.5 g of quercetin intravenously once a day for 10 days. Patients of the group II (30) received to basic therapy.
RESULTS: Results: After the treatment in patients of the group I general weakness decreased, body temperature normalized, improved saturation indicators, the level of acute-phase parameters (interleukin-6, CRP and ferritin) significantly decreased, a positive effect of quercetin on the level of D-dimer in blood serum was noted, indices of pericapillary edema and hemosiderin deposition significantly decreased, indices diameter of the arterial part of the capillary and capillary network density significantly increased.
CONCLUSION: Conclusions: The use of quercetin against the background of basic therapy in patients with COVID-19 and concomitant T2DM reliably reduces the level of acute-phase indices, has an important clinical significance for reducing endothelial dysfunction and for preventing thrombotic complications.